SMC Update - September 2023
The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Rimegepant (Vydura®) has been accepted for restricted use as preventive treatment of episodic migraine in adults who have at least four migraine attacks per month. The restrictions limits use to patients who have at least 4 migraine attacks per month, but fewer than 15 headache days per month and who have had prior failure on three or more migraine preventive treatments.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
| « CKS Updates - August 2023 | NICE Guidance - September 2023 » |
Leave a Comment